Investment Strategy

BioPharma Credit aims to generate long-term shareholder returns, principally in the form of sustainable income distributions from exposure to the life sciences industry.

The fund will seek to achieve its investment objective primarily through investments in debt assets secured by royalties or other cash flows derived from sales of approved life sciences products. Subject to certain restrictions and limitations, the fund may also invest in unsecured debt and equity issued by companies in the life sciences.

The Investment Manager will select investment opportunities based upon in-depth, rigorous analysis of the life sciences products backing an investment as well as the legal structure of the investment. A key component of this process is to examine future sales potential of the relevant product which is affected by several factors, including but not limited to; clinical utility, competition, patent estate, pricing, reimbursement (insurance coverage), marketer strength, track record of safety, physician adoption and sales history.

The fund will seek to build a diversified portfolio by investing across a range of different forms of assets issued by a variety of borrowers. In particular, no more than 25 per cent. of the Company’s gross assets will be exposed to any single borrower.

Portfolio Companies

October 2024

$219,000,000

Insmed

October 2024

$100,000,000

Geron

October 2024

$35,000,000

Atec

July 2024

$290,000,000

Collegium

May 2024

$200,000,000

Novocure

April 2024

$100,000,000

Tarsus

March 2024

$50,000,000

UroGen

May 2023

$137,500,000

Reata

April 2023

$180,000,000

BioCryst

December 2021

$62,500,000

Evolus

September 2019

$71,500,000

Optinose

December 2017

$150,000,000

Bristol Myers Squibb

Past Investments

April 2023

$62,500,000

Immunogen

November 2022

$50,000,000

Immunocore

October 2022

$140,000,000

Insmed

March 2022

$50,000,000

UroGen

February 2022

$325,000,000

Collegium

January 2022

$125,000,000

Coherus

March 2021

$150,000,000

LumiraDX

February 2020

$165,000,000

Collegium

December 2019

$132,500,000

GBT

December 2019

$350,000,000

Sarepta

November 2019

$50,000,000

Akebia

November 2019

$110,000,000

Epizyme

May 2019

$80,000,000

Biodelivery

September 2018

$150,000,000

Amicus

May 2018

$194,000,000

Sebela

February 2018

$150,000,000

Novocure

December 2017

$166,000,000

Lexicon

November 2017

$370,000,000

Tesaro
Consent Preferences
Change Cookie Settings

Cookie consent: Undecided